This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Schmauss, D. Articles by Weis, M. Search for Related Content PubMed PubMed Citation Articles by Schmauss, D. Articles by Weis, M. Related Collections Pathophysiology Other arteriosclerosis Transplantation Coronary imaging: angiography/ultrasound/Doppler/CC CV surgery: transplantation, ventricular assistance, cardiomyopathy Mechanism of atherosclerosis/growth factors Other Vascular biology

(Circulation. 2008;117:2131-2141.)
© 2008 American Heart Association, Inc.

Contemporary Reviews in Cardiovascular Medicine

Cardiac Allograft Vasculopathy

Recent Developments

Daniel Schmauss, MD; Michael Weis, MD

From Medizinische Klinik und Poliklinik I, University Hospital Grosshadern, Munich, Germany.

Correspondence to Michael Weis, Medizinische Klinik und Poliklinik I, University Hospital Munich-Grosshadern, Marchioninistrasse 15, 81377 Munich, Germany. E-mail michaweis{at}yahoo.com

Cardiac allograft vasculopathy (CAV) continues to limit the long-term success of cardiac transplantation. Recent insights have underscored the fact that innate and adaptive immune responses are involved in the pathogenesis of CAV. Vascular lesions are the result of cumulative endothelial injuries induced both by alloimmune responses and by nonspecific insults (including ischemia-reperfusion injury, viral infections, and metabolic disorders) in the context of impaired repair mechanisms. Intravascular ultrasound is the most sensitive method for detection of CAV, and progressive intimal thickening in the first posttransplant year identifies patients at high risk for future cardiovascular events. Encouraging results with regard to the detection of CAV by noninvasive methods should be an incentive to apply routine noninvasive imaging during mid- to long-term follow-up. Improved immunosuppressive drugs, including mycophenolate mofetil and proliferation signal inhibitors, as well as statins (in part via immunomodulation), have beneficial effects on CAV progression, although there is still a need to confirm the impact of vasodilators in improving outcome after heart transplantation. Coronary revascularization for CAV is only palliative, with no long-term survival benefit. Three main strategies for CAV prevention are currently under investigation: inhibition of growth factors and cytokines, cell therapy, and tolerance induction. However, because individual responses to an allograft change over time, assays to monitor the recipient’s immune response and individualized methods for therapeutic immune modulation are clearly needed.

Key Words: coronary disease • immunology • inflammation • microcirculation • transplantation

This article has been cited by other articles:

				J. D. Estep, D. J. Shah, S. F. Nagueh, J. J. Mahmarian, G. Torre-Amione, and W. A. Zoghbi The Role of Multimodality Cardiac Imaging in the Transplanted Heart J. Am. Coll. Cardiol. Img., September 1, 2009; 2(9): 1126 - 1140. [Abstract] [Full Text] [PDF]

				R. J. Novick Immediate Postoperative Care of the Heart Transplant Recipient: Perils and Triumphs Seminars in Cardiothoracic and Vascular Anesthesia, June 1, 2009; 13(2): 95 - 98. [Abstract] [PDF]

				A. Schober Chemokines in Vascular Dysfunction and Remodeling Arterioscler Thromb Vasc Biol, November 1, 2008; 28(11): 1950 - 1959. [Abstract] [Full Text] [PDF]

				P. J. Goldschmidt-Clermont and C. Dong Contrast-Enhanced Magnetic Resonance Imaging as the Newest Tool to Detect Transplant Coronary Artery Disease J. Am. Coll. Cardiol., September 30, 2008; 52(14): 1168 - 1169. [Full Text] [PDF]